An observational study in Ischemic Heart Disease, sponsored by Samsung Medical Center. Active, not recruiting at 4 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Samsung Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Myocardial Ischemia by Samsung Medical Center — 3 open to participants now, 6 under way, none of them phase 3. Myocardial Ischemia · Samsung Medical Center.
Among the 13 studies in Myocardial Ischemia by Samsung Medical Center, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2016, is one of 10 observational ones, and was the 3rd registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →3 of the 13 studies in Myocardial Ischemia by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 18+
By country, each count listing its studies:
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2016.
This study's planned enrollment of 1,400 is above the median of 318 across 398 observational studies indexed under Myocardial Ischemia.
Median enrollment 850 across the 3 interventional studies, 902 across the 10 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
2 of the studies in Myocardial Ischemia by Samsung Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03030495Samsung Medical CenterRegistry of Comprehensive Imaging and Physiological Evaluation of Deferred Lesions Based on FFR | 2026-12-31 |
| NCT05444452Samsung Medical CenterGENOSS Coronary Stent Clinical Trial | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Myocardial Ischemia by Samsung Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The coronary artery system has 3 components with different functions: conductive epicardial coronary arteries, arterioles, and capillaries. When any one of these systems fails, myocardial ischemia can occur. Therefore, the presence of epicardial coronary artery stenosis is not necessarily a prerequisite for ischemic heart disease (IHD). Although it has not been established that microvascular disease is independent of macrovascular disease, clinical studies have consistently shown that the presence of microvascular disease is an independent predictor of poor clinical outcomes, especially in patients with acute myocardial infarction (MI).
The pressure-derived fractional flow reserve (FFR) index has become a standard invasive method to evaluate the functional significance of epicardial coronary artery stenosis, and clinical outcomes of FFR-guided percutaneous coronary intervention (PCI) have proven to be better than those of angiography-guided PCI or medical treatment. Although FFR-guided PCI has been reported to improve patient outcomes and FFR is now regarded as the gold-standard invasive method to assess the functional significance of coronary artery stenosis, there is still room for further improvement in the diagnosis and treatment of patients with high FFR. In the FAME II study, 14.6% of the registry arm (FFR > 0.80 and deferral of PCI) experienced persistent angina, and 9.0% of these patients had clinical events during a 2-year follow-up period.
Therefore, microvascular assessment using coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR) can provide additional diagnostic and prognostic insights for IHD patients, especially in those with high FFR.
Recently, Lee et al. (JACC 2016) investigated clinical outcomes among patients with high-FFR and deferred revascularization, according to physiologic classification using CFR and IMR. Lee et al. firstly presented that 7.0% of patients with high FFR had high IMR and low CFR and were regarded as having overt microvascular disease. Although the proportion of patients with high FFR who had overt microvascular disease was small, Group D had the poorest clinical outcomes during follow-up. The presence of overt microvascular disease was an independent prognostic factor in patients with high FFR. In addition, the presence of overt microvascular disease had additive prognostic value aside from clinical risk factors, with significantly improved discriminant function of the prediction model. These results suggest that the invasive physiologic assessment for microvascular disease combined with CFR and IMR can help identify patients at high risk for future cardiovascular events among those with high FFR.
Previous studies have shown that the presence of microvascular disease is associated with a higher risk of cardiovascular events such as cardiac death, MI, or revascularization in patients without flow-limiting epicardial stenosis. Several mechanisms have been proposed for the association of microvascular disease and poor clinical outcomes. In addition to myocardial ischemia, microvascular disease is reported to be associated with endothelial dysfunction and inflammatory activity that precedes intimal thickening, lipid deposition in the macrovascular system, and coronary vasomotor dysfunction. In a study by Dhawan et al., coronary microvascular dysfunction in patients with non-obstructive coronary artery disease was associated with higher serum high-sensitivity C-reactive protein and a higher frequency of thin-cap fibroatheroma.
In the Lee et al.'s study, the higher clinical event rates in patients with overt microvascular disease resulted from cardiac death and revascularization rates higher than those of the other groups. These results imply that the presence of overt microvascular disease can induce accentuated atherosclerotic progression and subsequent clinical events including cardiac death and ischemia-driven repeat revascularization.
Therefore, the IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions with Contemporary Medical Treatment based on Fractional Flow Reserve-guided Strategy (IMPACT-FFR registry) was designed to compare the risk of atherosclerotic plaque progression and subsequent clinical events between deferred lesions with or without over microvascular disease, defined as physiological classification and also to explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment.
Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size ≥2.5 mm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fractional flow reserve\>0.80, coronary flow reserve\<2 \& Index of microvascular resistance\>25U
Device: Comprehensive physiologic evaluation · Device: Intravascular imaging devices
Fractional flow reserve\>0.80, coronary flow reserve\>2 \& Index of microvascular resistance\<25U
Device: Comprehensive physiologic evaluation · Device: Intravascular imaging devices
Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
Also known as: Comprehensive physiologic evaluation using pressure-temperature sensor wire
Intravascular ultrasound or optical coherence tomography
Also known as: Intravascular ultrasound or optical coherence tomography
patient-oriented composite outcome
a composite of all-cause death, MI, any repeat revascularization
Time frame: 24 months
patient-oriented composite outcome
a composite of all-cause death, MI, any repeat revascularization
Time frame: 12 months
patient-oriented composite outcome
a composite of all-cause death, MI, any repeat revascularization
Time frame: 60 months
All-cause death
All-cause death
Time frame: 24 months
cardiac death
cardiac death
Time frame: 24 months
Target-vessel nonfatal MI
Target-vessel nonfatal MI
Time frame: 24 months
Non-target vessel nonfatal MI
Non-target vessel nonfatal MI
Time frame: 24 months
All-cause nonfatal MI
All-cause nonfatal MI
Time frame: 24 months
Seattle Angina Questionnaires
Angina severity measured with Seattle Angina Questionnaires
Time frame: 24 months
Change in normalized total atheroma volume
TAVnormalized = \[Σ (EEM CSA - lumen CSA) / no. of images in pullback images in cohort\] X median no. of images in cohort
Time frame: 12 months
Change in total atheroma volume index
Indexed total atheroma volume (TAVi): Σ(EEM CSA -lumen CSA)/plaque length
Time frame: 12 months
Change in fibrous cap thickness by OCT
Change in fibrous cap thickness by OCT at 12-month
Time frame: 12 months
Change in Plaque burden at minimum lumen area site
Change in Plaque burden at minimum lumen area site at 12-month Plaque burden = (EEM-MLA)/EEM x 100
Time frame: 12 months
Change in Fractional flow reserve
Change in Fractional flow reserve at 12-month
Time frame: 12 months
Change in coronary flow reserve
Change in coronary flow reserve at 12-month
Time frame: 12 months
Change in index of microcirculatory resistance
Change in index of microcirculatory resistance at 12-month
Time frame: 12 months
Plan to share: Yes — After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked
No publications or documents are linked to this record.
Started Dec 2016 (actual). Primary completion is estimated for Dec 2026, 120 months after the start.
Of 165 non-industry observational studies under Myocardial Ischemia, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 127. This study's planned 120 months is above that.
Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.